GlassScriptPhysician profile
Charles C Tsai
NPI 1609825082
$11,631.83
in general payments reported to CMS, 2019-2025
21 companies · $3,647 in 2025
The $3,647 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $335 · 2021: $1,897 · 2022: $436 · 2023: $1,816 · 2024: $2,293 · 2025: $3,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053 · Travel and Lodging: $3,607 · Grant: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,052.94 |
| Travel and Lodging | $3,607.42 |
| Grant | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,335.23 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Capsure Sense |
| Abbott Laboratories | $2,221.20 | 2019-2025 | Aveir, Cardiomems, Gallant |
| Boston Scientific Corporation | $789.43 | 2019-2025 | General - Structural Heart, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $391.47 | 2019-2025 | Repatha |
| Novo Nordisk INC | $368.90 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.86 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $277.94 | 2023-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $171.62 | 2019 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Pfizer INC. | $123.23 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $104.14 | 2019 | |
| Biotronik INC. | $93.67 | 2025 | Amvia Edge, Selectra, Solia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.20 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $49.53 | 2023-2024 | |
| Akcea Therapeutics, INC. | $43.84 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $32.48 | 2019 | |
| Cathworks, INC. | $30.42 | 2020-2023 | Ffrangio |
| Gilead Sciences, INC. | $28.02 | 2019 | |
| Asahi Intecc USA, INC. | $21.47 | 2025 | Asahi Peripheral Vascular Wires |
| Shockwave Medical, INC | $20.08 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Scpharmaceuticals INC. | $14.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.